应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PFE 辉瑞
盘后交易 09-18 19:05:37 EDT
29.75
-0.08
-0.27%
盘后
29.77
+0.02
+0.07%
19:05 EDT
最高
30.14
最低
29.73
成交量
2,580万
今开
30.00
昨收
29.83
日振幅
1.37%
总市值
1,686亿
流通市值
1,683亿
总股本
56.67亿
成交额
7.71亿
换手率
0.46%
流通股本
56.59亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
第二次 "善达 "癌症审判以陪审团悬而未决告终
Reuters · 04:25
第二次 "善达 "癌症审判以陪审团悬而未决告终
辉瑞下跌1.23%,报29.7美元/股
金融界 · 09-18 00:49
辉瑞下跌1.23%,报29.7美元/股
BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 "引人入胜
Reuters · 09-16 19:15
BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 "引人入胜
辉瑞公布博瑞纳®CROWN研究亚洲亚组结果,63%ALK阳性晚期非小细胞肺癌患者五年后仍未发生疾病进展
美港电讯 · 09-15
辉瑞公布博瑞纳®CROWN研究亚洲亚组结果,63%ALK阳性晚期非小细胞肺癌患者五年后仍未发生疾病进展
辉瑞“增重药”取得积极实验结果 有望填补致命病程“无药可用”现状
新浪财经 · 09-15
辉瑞“增重药”取得积极实验结果 有望填补致命病程“无药可用”现状
研究显示辉瑞药物帮助癌症患者恢复体重
环球市场播报 · 09-14
研究显示辉瑞药物帮助癌症患者恢复体重
研究显示,辉瑞公司Ponsegromab有助于癌症患者恢复体重。
美港电讯 · 09-14
研究显示,辉瑞公司Ponsegromab有助于癌症患者恢复体重。
辉瑞推动 BRAF 肺癌突变检测以扩大 Braftovi 的市场
Reuters · 09-14
辉瑞推动 BRAF 肺癌突变检测以扩大 Braftovi 的市场
辉瑞20价肺炎疫苗上市申请获受理
中新经纬 · 09-14
辉瑞20价肺炎疫苗上市申请获受理
Fulcrum Therapeutics洛司马匹德三期临床试验失利,股价重挫逾60%
华尔街洞察 · 09-13
Fulcrum Therapeutics洛司马匹德三期临床试验失利,股价重挫逾60%
辉瑞下跌1.25%,报29.29美元/股
金融界 · 09-12
辉瑞下跌1.25%,报29.29美元/股
听取建议、回应诉求 广东省举办外资企业圆桌会
美港电讯 · 09-05
听取建议、回应诉求 广东省举办外资企业圆桌会
Vaxcyte(PCVX.US)盘前飙涨33% 旗下肺炎球菌结合疫苗显示出与辉瑞(PFE.US)竞品相似安全性
智通财经 · 09-03
Vaxcyte(PCVX.US)盘前飙涨33% 旗下肺炎球菌结合疫苗显示出与辉瑞(PFE.US)竞品相似安全性
捡便宜?美股波动后,两只成长股显露出长期投资价值
Motley Fool · 08-30
捡便宜?美股波动后,两只成长股显露出长期投资价值
特拉华州最高法院将审理制药商提出的终止 Zantac 诉讼的上诉
Reuters · 08-28
特拉华州最高法院将审理制药商提出的终止 Zantac 诉讼的上诉
辉瑞(PFE)开设网站直接向患者销售药品
金吾财讯 · 08-27
辉瑞(PFE)开设网站直接向患者销售药品
效仿礼来发掘新市场,辉瑞开设网站直接向患者销售药品
智通财经 · 08-27
效仿礼来发掘新市场,辉瑞开设网站直接向患者销售药品
辉瑞推出偏头痛和呼吸系统产品新网站
Reuters · 08-27
辉瑞推出偏头痛和呼吸系统产品新网站
【金十数据整理:每日美股市场要闻速递(8月23日 周五)】个股新闻1. FDA批准辉瑞(PFE.N)与Moderna(MRNA.
美港电讯 · 08-23
【金十数据整理:每日美股市场要闻速递(8月23日 周五)】个股新闻1. FDA批准辉瑞(PFE.N)与Moderna(MRNA.
分析-Ozempic 上榜华尔街 2027 年医疗保险药品谈判名单
Reuters · 08-23
分析-Ozempic 上榜华尔街 2027 年医疗保险药品谈判名单
加载更多
公司概况
公司名称:
辉瑞
所属市场:
NYSE
上市日期:
--
主营业务:
辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源,通过发现、开发、制造和分销保健产品(包括创新药物和疫苗),为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作,致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作,支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
发行价格:
--
{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":29.75,"timestamp":1726689600000,"preClose":29.83,"halted":0,"volume":25802577,"hourTrading":{"tag":"盘后","latestPrice":29.7695,"preClose":29.75,"latestTime":"19:05 EDT","volume":903344,"amount":26875264.489216,"timestamp":1726700730471},"delay":0,"floatShares":5658788891,"shares":5666695064,"eps":-0.468777,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.08,"latestTime":"09-18 19:05:37 EDT","open":30,"high":30.14,"low":29.7301,"amount":770979349.395072,"amplitude":0.013741,"askPrice":29.78,"askSize":2,"bidPrice":29.73,"bidSize":231,"shortable":3,"etf":0,"ttmEps":-0.468777,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1726704000000},"adr":0,"listingDate":-819144000000,"adjPreClose":29.83,"adrRate":0,"dividendRate":0.055798,"preHourTrading":{"tag":"盘前","latestPrice":29.98,"preClose":29.83,"latestTime":"09:29 EDT","volume":80455,"amount":2402590.01206,"timestamp":1726666199069},"postHourTrading":{"tag":"盘后","latestPrice":29.7695,"preClose":29.75,"latestTime":"19:05 EDT","volume":903344,"amount":26875264.489216,"timestamp":1726700730471},"volumeRatio":0.916633,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1729224000000,"strike":"28.0","timestamp":1726667549338,"price":0.1599999964237213,"volume":9700,"amount":155200,"type":"-"},{"symbol":"PFE","call":false,"expireDate":1729224000000,"strike":"29.0","timestamp":1726666715012,"price":0.3100000023841858,"volume":4000,"amount":124000,"type":"*"}]},"impliedVol":0.2573,"impliedVolPercentile":0.1587},"requestUrl":"/m/hq/s/PFE/","defaultTab":"news","newsList":[{"id":"2468547295","title":"第二次 \"善达 \"癌症审判以陪审团悬而未决告终","url":"https://stock-news.laohu8.com/highlight/detail?id=2468547295","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468547295?lang=zh_cn&edition=full","pubTime":"2024-09-19 04:25","pubTimestamp":1726691147,"startTime":"0","endTime":"0","summary":" * 芝加哥 \"善达\"癌症案最新审判中的陪审团悬而未决 * 与葛兰素史克和辉瑞达成和解后,勃林格殷格翰公司成为唯一被告 * 因NDMA致癌问题,美国食品药品管理局于 2020 年停用善达 Brendan Pierson 路透9月18日 - 据一名伊利诺伊州男子的律师称,该男子称因服用停产的胃灼热药善达克而患上前列腺癌,但芝加哥的陪审员未能就勃林格殷格翰公司是否必须向该男子支付赔偿金达成一致意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","BK4533","LU0306806265.USD","LU0170899867.USD","BK4588","BK4550","IE00BBT3K403.USD","LU0058720904.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0321505439.SGD","SG9999013999.USD","BK4007","BK4581","IE00BLSP4239.USD","SG9999003800.SGD","LU1066053197.SGD","LU1057294990.SGD","SG9999001176.SGD","IE00B19Z3581.USD","IE00BLSP4452.SGD","PFE","BK4592","LU0306807586.USD","LU0225771236.USD","BK4585","LU0122379950.USD","IE0002270589.USD","LU0289739699.SGD","LU0985481810.HKD","LU1066051498.USD","SG9999001176.USD","BK4534","LU0234572021.USD","SG9999002224.SGD","LU0868494617.USD","LU1023059063.AUD","SG9999002232.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","BK4568","LU0321505868.SGD","LU0225284248.USD","LU1894683348.USD","LU1894683264.USD","SG9999011175.SGD"],"gpt_icon":1},{"id":"2468362924","title":"辉瑞下跌1.23%,报29.7美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2468362924","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468362924?lang=zh_cn&edition=full","pubTime":"2024-09-18 00:49","pubTimestamp":1726591764,"startTime":"0","endTime":"0","summary":"9月18日,辉瑞(PFE)盘中下跌1.23%,截至00:49,报29.7美元/股,成交3.36亿美元。财务数据显示,截至2024年06月30日,辉瑞收入总额281.62亿美元,同比减少10.57%;归母净利润31.56亿美元,同比减少59.9%。大事提醒:9月16日,辉瑞获Cantor Fitzgerald重申评级Overweight,目标价45美元。10月29日,辉瑞将披露2024财年三季报(数据来源于纳斯达克官网,预计披露日期为美国当地时间,实际披露日期以公司公告为准)。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/18004943313752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["IE00BLSP4452.SGD","PFE","IE000M9KFDE8.USD","LU0321505868.SGD","BK4588","LU0985481810.HKD","SG9999003800.SGD","IE00BLSP4239.USD","LU0058720904.USD","BK4568","LU0289739699.SGD","LU1066051498.USD","LU0306807586.USD","BK4534","LU0321505439.SGD","LU0456855351.SGD","SG9999001176.SGD","SG9999001176.USD","SG9999011175.SGD","BK4533","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","LU0225284248.USD","LU0306806265.USD","SG9999002232.USD","LU1057294990.SGD","LU0225771236.USD","LU1894683264.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4550","LU0234572021.USD","LU1023059063.AUD","SG9999002224.SGD","SGXZ57979304.SGD","LU1894683348.USD","LU1066053197.SGD","BK4581","IE0002270589.USD","BK4007","BK4592","LU0868494617.USD"],"gpt_icon":0},{"id":"2467061816","title":"BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 \"引人入胜","url":"https://stock-news.laohu8.com/highlight/detail?id=2467061816","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467061816?lang=zh_cn&edition=full","pubTime":"2024-09-16 19:15","pubTimestamp":1726485344,"startTime":"0","endTime":"0","summary":" 9月16日 - ** 券商Guggenheim指出,辉瑞公司 的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\";并表示,在预计于明年公布治疗心力衰竭的中期数据之前,投资者的兴趣可能会增加。** PFE 在欧洲肿瘤内科学会 上公布了该实验药物的数据,结果显示癌症恶病质患者的体重与安慰剂相比有所增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0985320562.USD","LU1506573853.SGD","LU0256863902.USD","JNJ","LU0306807586.USD","IE00B7SZLL34.SGD","LU1934455194.USD","LU1917777945.USD","LU0114720955.EUR","LU0306806265.USD","PFE","BK4588","IE00B2B36J28.USD","LU0545039389.USD","LU0070302665.USD","LU0310800379.SGD","LU1032955483.USD","LU1934455277.USD","IE0002141913.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU0198837287.USD","LU0266013472.USD","LU1066053197.SGD","LU0985481810.HKD","BK4592","LU0640476718.USD","LU1430594728.SGD","ABBV","LU0889566641.SGD","LU1196500208.SGD","LU0170899867.USD","LU1221951046.USD","LU1059921491.USD","BK4139","BMY","LU1941712264.USD","LU0265550946.USD","LU1883839398.USD","LU0949170772.SGD","BK4504","LU0029864427.USD","LU0225284248.USD","MRK","LU0310799852.SGD","LU2242652126.USD","LU0738911758.USD","LU0106261372.USD","LU1221951129.SGD"],"gpt_icon":0},{"id":"2467027448","title":"辉瑞公布博瑞纳®CROWN研究亚洲亚组结果,63%ALK阳性晚期非小细胞肺癌患者五年后仍未发生疾病进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2467027448","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467027448?lang=zh_cn&edition=full","pubTime":"2024-09-15 10:28","pubTimestamp":1726367288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4550","PFE","IE00BLSP4452.SGD","BK4533","LU0306807586.USD","LU1066053197.SGD","LU0868494617.USD","SG9999001176.USD","LU0122379950.USD","LU0225284248.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","BK4500","SG9999002232.USD","LU0306806265.USD","BK4007","LU0289739699.SGD","IE00B19Z3581.USD","SG9999003800.SGD","BK4534","BK4008","BK4568","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU1066051498.USD","IE000M9KFDE8.USD","SG9999001176.SGD","ALK","IE0002270589.USD","LU1057294990.SGD","BK4585","BK4588","LU0170899867.USD","SG9999011175.SGD","LU1894683264.USD","LU0456855351.SGD","SG9999013999.USD","LU0321505868.SGD","LU0321505439.SGD","BK4581","IE00BBT3K403.USD","BK4592","LU0225771236.USD","LU0985481810.HKD","IE00BLSP4239.USD","LU1883839398.USD","LU1894683348.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2467853028","title":"辉瑞“增重药”取得积极实验结果 有望填补致命病程“无药可用”现状","url":"https://stock-news.laohu8.com/highlight/detail?id=2467853028","media":"新浪财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467853028?lang=zh_cn&edition=full","pubTime":"2024-09-15 06:47","pubTimestamp":1726354033,"startTime":"0","endTime":"0","summary":" 就在“减肥药双雄”叱咤资本市场之际,医药股领域上一个版本的王者辉瑞给分析师们端出了一个新的看点——能帮助多种慢性疾病晚期患者提升体重的新药。 辉瑞周六发布公告称,公司旗下单克隆抗体药物ponsegromab在一项针对癌症恶病质的Ⅱ期实验中取得积极结果,患者体重、肌肉质量、生活质量和身体功能各方面均出现改善。尽管这种状况非常严重,但目前尚无获得FDA批准的恶病质药物。","market":"us","thumbnail":"http://n.sinaimg.cn/spider20240915/600/w1357h843/20240915/1682-50134e2d88dff989e8ce5c0301262f24.jpg","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/spider20240915/600/w1357h843/20240915/1682-50134e2d88dff989e8ce5c0301262f24.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-09-15/doc-incpefcy4455609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4534","LU1894683264.USD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","SG9999011175.SGD","LU0868494617.USD","LU1023059063.AUD","LU0225771236.USD","BK4588","IE000M9KFDE8.USD","BK4592","LU1066053197.SGD","SG9999003800.SGD","BK4550","LU1883839398.USD","LU0122379950.USD","PFE","IE00B19Z3581.USD","SG9999013999.USD","SG9999001176.SGD","LU0225284248.USD","LU0306806265.USD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","SG9999002232.USD","LU0170899867.USD","LU1057294990.SGD","BK4568","IE0002270589.USD","LU0234572021.USD","BK4533","LU0058720904.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU1066051498.USD","LU0306807586.USD","LU0985481810.HKD","BK4585","LU1894683348.USD","SG9999001176.USD","BK4581","IE00BLSP4452.SGD","LU0456855351.SGD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2467401860","title":"研究显示辉瑞药物帮助癌症患者恢复体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2467401860","media":"环球市场播报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467401860?lang=zh_cn&edition=full","pubTime":"2024-09-14 22:02","pubTimestamp":1726322542,"startTime":"0","endTime":"0","summary":" 辉瑞公司一项中期研究显示这种用于癌症减肥的实验性药物可以帮助患者恢复体重为治疗这种危险的肌肉萎缩疾病带来了新希望。研究表明高达30%所有癌症死亡中的1%是由恶病质引起的约80%的晚期癌症患者受到这种情况的影响。目前尚无批准用于治疗该病的药物。 辉瑞在一项2期研究中招募了187名GDF-15水平较高的癌症患者与安慰剂相比测试ponsegromab对体重的影响。研究结果显示这些患者的食欲、体力活动水平和骨骼肌也有所改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2024-09-14/doc-incpcuqk5054118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["SG9999011175.SGD","LU0306806265.USD","IE00BBT3K403.USD","LU1066051498.USD","LU0225771236.USD","LU0058720904.USD","BK4550","BK4568","PFE","SG9999001176.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU1023059063.AUD","IE00BLSP4452.SGD","SGXZ57979304.SGD","LU0170899867.USD","LU0234572021.USD","LU1894683348.USD","IE0002270589.USD","IE00B19Z3581.USD","LU0985481810.HKD","SG9999002232.USD","BK4007","IE00B19Z3B42.SGD","LU0225284248.USD","BK4585","LU0321505439.SGD","SG9999001176.USD","SG9999013999.USD","BK4588","BK4533","LU0122379950.USD","SG9999002224.SGD","LU0321505868.SGD","LU0868494617.USD","LU0306807586.USD","LU1066053197.SGD","BK4581","BK4534","IE00BLSP4239.USD","LU0456855351.SGD","BK4592","IE000M9KFDE8.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2467898097","title":"研究显示,辉瑞公司Ponsegromab有助于癌症患者恢复体重。","url":"https://stock-news.laohu8.com/highlight/detail?id=2467898097","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467898097?lang=zh_cn&edition=full","pubTime":"2024-09-14 20:58","pubTimestamp":1726318704,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["PFE","LU0306807586.USD","BK4592","SG9999002224.SGD","SG9999002232.USD","SG9999013999.USD","LU0985481810.HKD","BK4534","BK4550","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0225284248.USD","IE00BBT3K403.USD","LU0170899867.USD","LU0321505439.SGD","LU1023059063.AUD","LU1057294990.SGD","BK4588","LU0058720904.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU1066053197.SGD","BK4533","LU1066051498.USD","LU0456855351.SGD","LU0234572021.USD","LU0306806265.USD","LU1894683348.USD","LU1894683264.USD","BK4585","SG9999001176.USD","SG9999003800.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU0122379950.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4568","LU0289739699.SGD","BK4581","IE0002270589.USD","SG9999001176.SGD","BK4007","LU1883839398.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2467644410","title":"辉瑞推动 BRAF 肺癌突变检测以扩大 Braftovi 的市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2467644410","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467644410?lang=zh_cn&edition=full","pubTime":"2024-09-14 16:15","pubTimestamp":1726301709,"startTime":"0","endTime":"0","summary":"自去年以来,Braftovi 和 Mektovi 的组合疗法已被批准用于治疗有突变的非小细胞肺癌患者。根据 LSEG 的数据,辉瑞去年销售了近 4 亿美元的 Braftovi 和 Mektovi,但分析师目前预测这两种药物不会有大幅增长。Boshoff说,Braftovi可以扩大市场的一个领域是结直肠癌,BRAF突变的癌症占癌症的10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"辉瑞推动 BRAF 肺癌突变检测以扩大 Braftovi 的市场","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1066051498.USD","BK4533","SG9999011175.SGD","BK4592","IE0002270589.USD","SGXZ57979304.SGD","LU0170899867.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306806265.USD","LU0868494617.USD","SG9999013999.USD","BK4588","LU0225284248.USD","LU0234572021.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4239.USD","BK4550","IE00B19Z3581.USD","BK4534","SG9999001176.USD","LU0058720904.USD","LU1057294990.SGD","BK4581","LU1023059063.AUD","LU1894683264.USD","IE00BBT3K403.USD","BK4568","IE00B19Z3B42.SGD","BK4585","LU0985481810.HKD","PFE","LU0289739699.SGD","LU1883839398.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU1894683348.USD","SG9999001176.SGD","LU0321505868.SGD","BK4007","SG9999003800.SGD","LU0321505439.SGD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2467059210","title":"辉瑞20价肺炎疫苗上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2467059210","media":"中新经纬","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467059210?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:35","pubTimestamp":1726284912,"startTime":"0","endTime":"0","summary":"(王玉玲)13日,国家药品监督管理局药品审评中心官网显示,辉瑞公司的20价肺炎球菌...","market":"hk","thumbnail":"http://www.jwview.com/jingwei/09-14/U1049P902T1D606639F10DT20240914113512.jpg","type":0,"news_type":0,"thumbnails":["http://www.jwview.com/jingwei/09-14/U1049P902T1D606639F10DT20240914113512.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.jwview.com/jingwei/html/09-14/606639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"zxjw_stock","symbols":["BK4533","SG9999002224.SGD","LU0225284248.USD","LU1023059063.AUD","LU0868494617.USD","LU1883839398.USD","LU0122379950.USD","LU0306807586.USD","SG9999003800.SGD","LU0225771236.USD","BK4585","BK4534","IE0002270589.USD","SG9999001176.USD","LU0321505439.SGD","BK4550","SGXZ57979304.SGD","BK4568","LU1066053197.SGD","PFE","SG9999013999.USD","159646","SG9999011175.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0234572021.USD","LU0058720904.USD","IE000M9KFDE8.USD","LU0170899867.USD","BK4588","IE00BLSP4239.USD","LU0456855351.SGD","SG9999002232.USD","SG9999001176.SGD","BK4007","LU1894683348.USD","LU0985481810.HKD","LU1066051498.USD","LU1057294990.SGD","BK4592","LU0306806265.USD","BK4581","LU0289739699.SGD","IE00BLSP4452.SGD","LU1894683264.USD"],"gpt_icon":1},{"id":"1179497928","title":"Fulcrum Therapeutics洛司马匹德三期临床试验失利,股价重挫逾60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179497928","media":"华尔街洞察","labels":["analysis"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179497928?lang=zh_cn&edition=full","pubTime":"2024-09-13 08:20","pubTimestamp":1726186800,"startTime":"0","endTime":"0","summary":"纳斯达克上市公司$Fulcrum Therapeutics$, Inc.今日股价暴跌超过60%,主要原因是其主导候选药物洛司马匹德未能在治疗肌肉营养不良症的关键三期临床试验REACH中达到预期目标。根据Fulcrum发布的声明,REACH试验未能达到评估肌肉力量恢复的主要终点指标,次要终点指标也未达到显著性水平。Fulcrum CEO Alex C. Sapir表示,鉴于这些不利结果,公司将暂停洛司马匹德在FSHD适应证的进一步开发。这对Fulcrum无疑是一个重大打击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1366192091.USD","LU0648001328.SGD","PRO","LU0130102774.USD","BAC","LU1066053197.SGD","LU2462157665.USD","LU1718418525.SGD","LU2237443549.SGD","LU0070302665.USD","LENZ","LU0170899867.USD","BK4550","LU2237443465.HKD","IE00B2B36J28.USD","LU1093756168.USD","RNA","PFE","SGXZ57979304.SGD","BK4552","BK1583","SNY","IE00B7SZLL34.SGD","BK1576","IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","LU1093756325.SGD","LU0234570918.USD","BK4139","BK4581","CRSP","03165","LU2237443978.SGD","VRTX","BK4505","RHHBY","BK4568","LU1668664300.SGD","BK1141","LU2237443622.USD","SCD","LU1883839398.USD","LU2456880835.USD","LU0208291251.USD","LU1201861165.SGD","03347","FULC","MFI","BK4007","BK4207","BK4556","BK4127","IE00BFTCPJ56.SGD","BLUE","LU0889565916.HKD","LU0079474960.USD"],"gpt_icon":0},{"id":"2466137203","title":"辉瑞下跌1.25%,报29.29美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466137203","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466137203?lang=zh_cn&edition=full","pubTime":"2024-09-12 21:37","pubTimestamp":1726148247,"startTime":"0","endTime":"0","summary":"9月12日,辉瑞(PFE)盘中下跌1.25%,截至21:37,报29.29美元/股,成交7249.26万美元。财务数据显示,截至2024年06月30日,辉瑞收入总额281.62亿美元,同比减少10.57%;归母净利润31.56亿美元,同比减少59.9%。大事提醒:9月9日,辉瑞获Cantor Fitzgerald重申评级Overweight,目标价45美元。10月29日,辉瑞将披露2024财年三季报(数据来源于纳斯达克官网,预计披露日期为美国当地时间,实际披露日期以公司公告为准)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/12213743225661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0456855351.SGD","BK4533","LU0306806265.USD","LU0170899867.USD","BK4588","BK4550","IE00BBT3K403.USD","LU0058720904.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0321505439.SGD","SG9999013999.USD","BK4007","BK4581","IE00BLSP4239.USD","SG9999003800.SGD","LU1066053197.SGD","LU1057294990.SGD","SG9999001176.SGD","IE00B19Z3581.USD","IE00BLSP4452.SGD","PFE","BK4592","LU0306807586.USD","LU0225771236.USD","BK4585","LU0122379950.USD","IE0002270589.USD","LU0289739699.SGD","LU0985481810.HKD","LU1066051498.USD","SG9999001176.USD","BK4534","LU0234572021.USD","SG9999002224.SGD","LU0868494617.USD","LU1023059063.AUD","SG9999002232.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","BK4568","LU0321505868.SGD","LU0225284248.USD","LU1894683348.USD","LU1894683264.USD","SG9999011175.SGD"],"gpt_icon":1},{"id":"2465594717","title":"听取建议、回应诉求 广东省举办外资企业圆桌会","url":"https://stock-news.laohu8.com/highlight/detail?id=2465594717","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465594717?lang=zh_cn&edition=full","pubTime":"2024-09-05 13:28","pubTimestamp":1725514113,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2087621335.USD","LU0306806265.USD","LU1150488218.USD","LU2505996681.GBP","XOM","LU2505996509.AUD","SG9999002224.SGD","LU0731783394.SGD","LU1074936037.SGD","KHC","LU0158827781.USD","LU0971552673.USD","LU1019632923.USD","LU0306807586.USD","LU0320765489.SGD","LU0466842654.USD","LU0787776722.HKD","LU1019634622.SGD","BK4570","LU1839511570.USD","LU0889566641.SGD","SIEGY","LU0795875169.SGD","LU1400636491.USD","BK4212","LU0742537680.HKD","LU1582987324.SGD","LU1119994140.HKD","LU2602419157.SGD","BK4504","PFE","LU1582986359.USD","03165","LU1582987597.SGD","LU0640476718.USD","BK4581","LU0300736492.USD","LU1046248800.SGD","LU0456855351.SGD","LU0985320562.USD","LU0742534661.SGD","SG9999002232.USD","ULVR.UK","LU0048573561.USD","WMT","BK4592","LU2592432038.USD","LU0550127509.SGD","LU1150488135.SGD","FDX"],"gpt_icon":0},{"id":"2464059228","title":"Vaxcyte(PCVX.US)盘前飙涨33% 旗下肺炎球菌结合疫苗显示出与辉瑞(PFE.US)竞品相似安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2464059228","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464059228?lang=zh_cn&edition=full","pubTime":"2024-09-03 20:40","pubTimestamp":1725367209,"startTime":"0","endTime":"0","summary":"智通财经获悉,Vaxcyte在周二宣布其实验性肺炎球菌多糖结合疫苗 VAX-31在1/2期试验中显示出与竞争对手辉瑞旗下产品Prevnar 20相似的安全性后,其股价在盘前上涨了约33%。根据这项研究的数据,该公司表示,在六个月的评估期内,所有剂量的VAX-31都具有良好的耐受性,与Prevnar 20相似。然而,与Prevnar 20相比,在VAX-31高剂量下,20种血清型中有18种的平均OPA免疫应答更高。基于这些结果,Vaxcyte 打算将临床中最广泛的PCV候选物VAX-31推进到成人3期项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","PFE","IE00BLSP4452.SGD","BK4533","LU0306807586.USD","LU1066053197.SGD","LU0868494617.USD","SG9999001176.USD","LU0122379950.USD","LU0225284248.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","159646","SG9999002232.USD","LU0306806265.USD","BK4007","LU0289739699.SGD","IE00B19Z3581.USD","SG9999003800.SGD","BK4139","BK4534","BK4568","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU1066051498.USD","IE000M9KFDE8.USD","SG9999001176.SGD","IE0002270589.USD","LU1057294990.SGD","BK4585","BK4588","LU0170899867.USD","SG9999011175.SGD","LU1894683264.USD","LU0456855351.SGD","SG9999013999.USD","LU0321505868.SGD","LU0321505439.SGD","BK4581","IE0009354923.USD","IE00BBT3K403.USD","BK4592","LU0225771236.USD","LU0985481810.HKD","IE00BLSP4239.USD","LU1883839398.USD","LU1894683348.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"1136047154","title":"捡便宜?美股波动后,两只成长股显露出长期投资价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1136047154","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136047154?lang=zh_cn&edition=full","pubTime":"2024-08-30 17:59","pubTimestamp":1725011953,"startTime":"0","endTime":"0","summary":"即使在牛市中,也不是所有股票都会一帆风顺。","market":"us","thumbnail":"https://static.tigerbbs.com/32f76f2b955be371110b877bebef37ba","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/32f76f2b955be371110b877bebef37ba"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/08/30/2-incredibly-cheap-growth-stocks-to-buy-now/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PFE","PYPL"],"gpt_icon":1},{"id":"2462434117","title":"特拉华州最高法院将审理制药商提出的终止 Zantac 诉讼的上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2462434117","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462434117?lang=zh_cn&edition=full","pubTime":"2024-08-28 02:37","pubTimestamp":1724783866,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透8月27日 - 美国特拉华州最高法院周二表示,将审理葛兰素史克 和其他制药商提出的上诉,以结束7万多起声称已停产的烧心药善达克(Zantac)会致癌的诉讼。葛兰素史克、辉瑞 、赛诺菲 和勃林格殷格翰要求法院推翻下级法院法官的命令,允许诉讼原告就所谓的癌症关联提供专家证词。这两家公司否认了这些指控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"gpt_icon":1},{"id":"2462948194","title":"辉瑞(PFE)开设网站直接向患者销售药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2462948194","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462948194?lang=zh_cn&edition=full","pubTime":"2024-08-27 22:40","pubTimestamp":1724769654,"startTime":"0","endTime":"0","summary":"金吾财讯 | 辉瑞(PFE)今日推出其用户友好型平台PfizerForAll.com,允许美国用户预约疫苗接种或与医生进行线上会面,医生可以开出新冠肺炎、偏头痛和其他疾病的处方药,然后将药品运送到患者家门口。辉瑞美国首席商务官阿米尔·马利克在接受采访时表示:“我们致力于实现改变患者生活的突破,但只有能够在人们需要时为他们提供所需的药物,这才是有效和有影响力的。”今年1月,礼来公司推出了LillyDirect门户网站,销售广受欢迎的肥胖和糖尿病治疗药物,这是大型制药公司首次直接向消费者推销产品。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"279336","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1066051498.USD","BK4533","SG9999011175.SGD","BK4592","IE0002270589.USD","SGXZ57979304.SGD","LU0170899867.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306806265.USD","LU0868494617.USD","SG9999013999.USD","BK4588","LU0225284248.USD","LU0234572021.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4239.USD","BK4550","IE00B19Z3581.USD","BK4534","SG9999001176.USD","LU0058720904.USD","LU1057294990.SGD","BK4581","LU1023059063.AUD","LU1894683264.USD","IE00BBT3K403.USD","BK4568","IE00B19Z3B42.SGD","BK4585","LU0985481810.HKD","PFE","LU0289739699.SGD","LU1883839398.USD","LU0122379950.USD","LU1894683348.USD","SG9999001176.SGD","LU0321505868.SGD","BK4007","SG9999003800.SGD","LU0321505439.SGD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2462162279","title":"效仿礼来发掘新市场,辉瑞开设网站直接向患者销售药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2462162279","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462162279?lang=zh_cn&edition=full","pubTime":"2024-08-27 21:10","pubTimestamp":1724764200,"startTime":"0","endTime":"0","summary":"今年 1 月,礼来公司推出了 LillyDirect 门户网站,销售广受欢迎的肥胖和糖尿病治疗药物,这是大型制药公司首次直接向消费者推销产品。直销还绕过了药品福利管理者等参与者,制药商称这些参与者会降低他们的收入并损害患者的药品获取。辉瑞表示,其平台已建立制衡机制,以防止任何不当影响。辉瑞可以利用销售增长。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172280.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"效仿礼来发掘新市场,辉瑞开设网站直接向患者销售药品","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","LU0306806265.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD","SG9999013999.USD","GB00BDT5M118.USD","LU0689472784.USD","IE00BK4W5L77.USD","BK4581","BK4568","LU0238689110.USD","LU0170899867.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1280957306.USD","LU0061475181.USD","LU0234572021.USD","SG9999001176.USD","LU0882574139.USD","PFE","LU0198837287.USD","LU1894683348.USD","LU0289739699.SGD","BK4592","LU0882574055.USD","IE00BBT3K403.USD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","LU0321505868.SGD","SGXZ57979304.SGD","LU0456855351.SGD","LU1551013342.USD","IE0009355771.USD","LU0097036916.USD","BK4007","LU1023059063.AUD","LU0256863811.USD","IE0004445239.USD","IE0002270589.USD","SG9999003800.SGD","LU0417517546.SGD","IE00BJLML261.HKD","LU0094547139.USD","LU0868494617.USD","IE00B1BXHZ80.USD","LU0985481810.HKD","SG9999011175.SGD","BK4534","LU0006306889.USD"],"gpt_icon":0},{"id":"2462150318","title":"辉瑞推出偏头痛和呼吸系统产品新网站","url":"https://stock-news.laohu8.com/highlight/detail?id=2462150318","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462150318?lang=zh_cn&edition=full","pubTime":"2024-08-27 18:45","pubTimestamp":1724755506,"startTime":"0","endTime":"0","summary":" Michael Erman 路透8月27日 - 辉瑞公司 正在推出一个新网站,以推广和改善其偏头痛和呼吸系统疾病的医疗服务。这家制药商周二表示,它推出了名为PfizerForAll的网站,通过提供远程医疗预约和诊断检测等服务,帮助患者获得COVID-19药物Paxlovid和偏头痛药物Nurtec等治疗。由于辉瑞的 COVID-19 疫苗和治疗市场每年缩水数十亿美元,投资者纷纷逃离辉瑞。辉瑞表示,该网站的新服务包括UpScriptHealth提供的远程健康咨询和Instacart 提供的送货选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","LU0122379950.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0234572021.USD","SG9999002224.SGD","LU0306806265.USD","IE0002270589.USD","PFE","SG9999001176.USD","BK4550","LU1023059063.AUD","BK4533","SG9999001176.SGD","LU0985481810.HKD","LU1057294990.SGD","LU0058720904.USD","IE00B19Z3581.USD","BK4585","SG9999013999.USD","LU0225284248.USD","LU1066053197.SGD","LU1894683264.USD","CART","LU0321505439.SGD","BK4588","SG9999002232.USD","IE00BLSP4239.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","SG9999011175.SGD","BK4007","LU0225771236.USD","LU1894683348.USD","LU1883839398.USD","LU0289739699.SGD","BK4534","BK4568","IE00BBT3K403.USD","BK4113","LU0170899867.USD","BK4581","LU1066051498.USD","LU0321505868.SGD","LU0306807586.USD","LU0868494617.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2461591355","title":"【金十数据整理:每日美股市场要闻速递(8月23日 周五)】个股新闻1. FDA批准辉瑞(PFE.N)与Moderna(MRNA.","url":"https://stock-news.laohu8.com/highlight/detail?id=2461591355","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461591355?lang=zh_cn&edition=full","pubTime":"2024-08-23 21:20","pubTimestamp":1724419202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1046422090.SGD","ZH","BX","LU1057294990.SGD","SG9999015952.SGD","159646","BK4501","EVS.SI","BK4565","VLVLY","SG9999014880.SGD","LU0058720904.USD","00175","LU1814569148.SGD","EM","02390","BK4504","SG9999018865.SGD","IE00BLSP4239.USD","LU1894683264.USD","GELYY","BK1589","LU0289739699.SGD","BK1521","LU1066051498.USD","PFE","UBER","LU1046421795.USD","LU0918141887.USD","LU0456855351.SGD","SG9999002224.SGD","LU1880383366.USD","BK4139","LU0719512351.SGD","IE00BBT3K403.USD","MRNA","BK4505","LU0880133367.SGD","80175","LU1883839398.USD","ROST","BABA","BK4502","SG9999002232.USD","LU0321505439.SGD","BK4503","IE0004445239.USD","LU0122379950.USD","09988","LU0052756011.USD"],"gpt_icon":0},{"id":"2461560288","title":"分析-Ozempic 上榜华尔街 2027 年医疗保险药品谈判名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2461560288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461560288?lang=zh_cn&edition=full","pubTime":"2024-08-23 20:00","pubTimestamp":1724414417,"startTime":"0","endTime":"0","summary":"监管机构将于 2025 年 2 月公布另外 15 种药物的名单。2022 年,医疗保险在该药物上的支出超过 46 亿美元。\"他将Ozempic列入了面临价格谈判的高折扣产品名单。诺和诺德表示,它保留了 Ozempic 上市价格的 60% 左右。辉瑞至少有两种药品Ibrance和Xtandi可能被列入2027年的名单。2028 年削减 2026 年,监管机构将宣布在 2028 年再对多达 15 种药品进行谈判,其中包括被称为 B 部分的医疗保险医院计划所涵盖的药品,以及此后每年多达 20 种药品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU1267930490.SGD","LU1934455277.USD","LU1934455863.HKD","LU0266013472.USD","LU0320765489.SGD","LU0256863902.USD","LU2242652126.USD","BK4581","PFE","LU1291159041.SGD","LU1941712264.USD","LU0708994859.HKD","LU0985481810.HKD","LU0198837287.USD","LU1917777945.USD","LU2133065610.SGD","LU2125154778.USD","IE00B2B36J28.USD","LU0943347566.SGD","LU0306806265.USD","LU0070302665.USD","LU0106261372.USD","LU0795875169.SGD","LU2242646821.SGD","LU1037948897.HKD","LU1074936037.SGD","LU1244550494.USD","MRK","IE00BJJMRZ35.SGD","LU0225284248.USD","LU0306807586.USD","BK4139","BK4007","LU1066053197.SGD","LU0256863811.USD","LU0795875086.SGD","IE00BLSP4452.SGD","LU0114720955.EUR","LU1718418525.SGD","BK4559","LU1934455194.USD","IE00B19Z3581.USD","BMY","LU0456855351.SGD","ABBV","BK4550","LU1244550221.USD","IE00B4R5TH58.HKD","LU0985320562.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.0883},{"period":"6month","weight":0.0785},{"period":"1year","weight":-0.1133},{"period":"ytd","weight":0.0361}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.0266},{"period":"6month","weight":0.0783},{"period":"1year","weight":0.2692},{"period":"ytd","weight":0.1846}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源,通过发现、开发、制造和分销保健产品(包括创新药物和疫苗),为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作,致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作,支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015985},{"month":4,"riseRate":0.6,"avgChangeRate":0.019475},{"month":5,"riseRate":0.511111,"avgChangeRate":0.008757},{"month":6,"riseRate":0.488889,"avgChangeRate":0.00215},{"month":7,"riseRate":0.488889,"avgChangeRate":0.01248},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.001198},{"month":9,"riseRate":0.466667,"avgChangeRate":0.004566},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}